Mechanism of action of trastuzumab and scientific update

Area of Science:

• Oncology
• Immunology
• Molecular Biology

Background:

• HER2-overexpressing breast cancer is a significant clinical challenge.
• Trastuzumab is a humanized monoclonal antibody targeting the p185(HER2) receptor.
• Understanding trastuzumab's mechanisms of action is crucial for optimizing cancer therapy.

Purpose of the Study:

• To elucidate the cellular and molecular mechanisms by which trastuzumab exerts its antitumor effects.
• To investigate the impact of trastuzumab on HER2 receptor expression and downstream signaling pathways.
• To explore the role of antibody-dependent cellular cytotoxicity and HER2 cleavage inhibition in trastuzumab's efficacy.

Main Methods:

• In vitro studies using HER2-overexpressing cancer cell lines.
• In vivo studies in relevant preclinical models.
• Analysis of HER2 receptor downregulation, p27 accumulation, and cell cycle progression.
• Assessment of antibody-dependent cellular cytotoxicity (ADCC).
• Investigation of metalloprotease-mediated HER2 cleavage.

Main Results:

• Trastuzumab treatment led to significant downregulation of the HER2 receptor.
• Accumulation of the cyclin-dependent kinase inhibitor p27 was observed, resulting in cell cycle arrest.
• Trastuzumab induced potent antibody-dependent cellular cytotoxicity in vivo.
• The antibody effectively inhibited constitutive HER2 cleavage by metalloproteases.

Conclusions:

• Trastuzumab demonstrates multifaceted anticancer activity against HER2-overexpressing breast cancer.
• Mechanisms include direct HER2 inhibition, cell cycle arrest, immune-mediated cytotoxicity, and prevention of receptor shedding.
• Inhibition of HER2 cleavage may be a key factor contributing to trastuzumab's clinical effectiveness.